Exploratory study of the expression of the serotonergic 5-HT4 receptor in Parkinson's disease

Prior treatment

• Treated with specific serotonin inhibitors (SSRIs), specific noradrenaline inhibitors (SNRIs), tricyclic antidepressants, monoamine oxidase inhibitors (MAOIs) and neuroleptics in the last 3 months
• Use of recreational drugs interfering with the serotonergic system (ecstasy, MDMA) or opioids (cannabis, opiates) in the last 3 months or chronic use
• Participation in the last year to a study using ionizing radiation or concomitant participation in another research project involving the human being that may interfere with the results or the conclusions of this study

Other illness

• Diagnosis other than Parkinson's disease ( for patient only)
• Cognitive impairment (MOCA score ≤26) (for healthy volunteers only)
• Current or past neurological or psychiatric pathology (for healthy volunteers only)

Other

• Deprivation of liberty by judicial or administrative decision, person subject to a legal protection measure
• BMI ≥ 35kg/m2
• Presence of depression (BDI-2 score ≥21), anxiety (Parkinson Anxiety Scale, PAS score ≥14) or apathy (STARKSTEIN score ≥14) - for healthy volunteers only
• Serious and progressive medical pathology
• Contraindication to magnetic resonance imaging (MRI) or positron emission tomography (PET)
• Exceeding the annual amount of compensation authorized for participation in research protocols

• Clinically established or probable diagnosis of Parkinson's disease according to the criteria defined by the Movement Disorder Society at a Hoehn and Yahr stage ≤ 3 (for patient only)
• Duration of disease progression between 2 and 8 years (for patient only)
• MoCA ≥ 20/30 (for patient only)
• Age between ≥ 50 and ≤ 85 years old
• if woman , postmenopausal woman
• Affiliated to a social security scheme or similar
• Having given their written consent to participate
• Level of study: ≥ 6 years of schooling
• No history of neurological or psychiatric disease (healthy volunteers only)